ENTITY
Broncus

Broncus (2216 HK)

21
Analysis
Health Care • China
Broncus is a medical device company focused on the research, development, manufacturing, and commercialization of innovative solutions for lung diseases. The company provides diagnostic solutions, lung cancer treatment solutions, and chronic obstructive pulmonary disease (COPD) solutions, including navigation platforms and interventional therapeutic devices like the InterVapor system and BroncAblate. Broncus was founded in 2012 and is headquartered in Hangzhou, China.
more
•01 Nov 2021 16:51

Microport MedBot IPO:  Thoughts on First Day Trading

Microport MedBot priced its IPO at HK$43.20 per share and we believe there is very limited upside to the company's shares as our SOTP valuation...

Share
•18 Oct 2021 15:33

MicroTech Medical IPO: Thoughts on First Day Trading

MicroTech priced its IPO at HK$30.50 per share which significantly overvalues the shares. We expect the company's shares to open poorly at its...

Share
•30 Sep 2021 09:05

Pre-IPO Infervision Medical Technology - Insights on Industry, Business and Concerns

This article mainly analyzed Infervision Medical Technology in terms of the AI medical industry characteristics, the business, the product layout,...

Logo
555 Views
Share
•26 Sep 2021 11:33

ECM Weekly (26th September 2021) - Hanyu Med, Abbisko, SenseTime, ANE, Nykaa, Prudential HK

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Logo
653 Views
Share
bearish•Broncus
•23 Sep 2021 19:19

Broncus IPO: Thoughts on First Day Trading

Though Broncus priced its IPO at the top-end of its price range, our reverse DCF model suggests that Broncus’ IPO is overvalued. We expect shares...

Share
x